streptogramin b has been researched along with nxl 103 in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (57.14) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Champney, WS; Mabe, S | 1 |
| Dupuis, M; Leclercq, R | 1 |
| Andes, D; Craig, WA | 1 |
| Appelbaum, PC; Bryskier, A; Hoellman, D; Lowther, J; Pankuch, GA | 1 |
| Politano, AD; Sawyer, RG | 1 |
| Parra-Ruiz, J; Rybak, MJ; Vidaillac, C; Winterfield, P | 1 |
| Cate, JH; Giacobbe, RA; Huang, J; Noeske, J; Olivier, NB; Zambrowski, M | 1 |
1 review(s) available for streptogramin b and nxl 103
| Article | Year |
|---|---|
NXL-103, a combination of flopristin and linopristin, for the potential treatment of bacterial infections including community-acquired pneumonia and MRSA.
Topics: Animals; Anti-Bacterial Agents; Bacterial Infections; Clinical Trials as Topic; Community-Acquired Infections; Cross Infection; Drug Combinations; Humans; Methicillin-Resistant Staphylococcus aureus; Pneumonia, Bacterial; Staphylococcal Infections; Streptogramin A; Streptogramin B | 2010 |
6 other study(ies) available for streptogramin b and nxl 103
| Article | Year |
|---|---|
A comparison of a new oral streptogramin XRP 2868 with quinupristin-dalfopristin against antibiotic-resistant strains of haemophilus influenzae, Staphylococcus aureus, and Streptococcus pneumoniae.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Drug Combinations; Drug Resistance, Bacterial; Haemophilus influenzae; Ribosomes; Staphylococcus aureus; Streptococcus pneumoniae; Streptogramin A; Streptogramin B; Virginiamycin | 2005 |
Activity of a new oral streptogramin, XRP2868, against gram-positive cocci harboring various mechanisms of resistance to streptogramins.
Topics: Administration, Oral; Anti-Bacterial Agents; Drug Combinations; Drug Evaluation, Preclinical; Drug Resistance, Microbial; Gram-Positive Cocci; Microbial Sensitivity Tests; Streptogramin A; Streptogramin B; Streptogramins | 2006 |
Pharmacodynamics of a new streptogramin, XRP 2868, in murine thigh and lung infection models.
Topics: Animals; Anti-Infective Agents; Area Under Curve; Bacteria; Bacterial Infections; Disease Models, Animal; Drug Combinations; Drug Evaluation; Lung; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Streptogramin A; Streptogramin B; Streptogramins; Thigh | 2006 |
Effects of various media on the activity of NXL103 (formerly XRP 2868), a new oral streptogramin, against Haemophilus influenzae.
Topics: Anti-Bacterial Agents; Culture Media; Dose-Response Relationship, Drug; Drug Combinations; Haemophilus influenzae; Microbial Sensitivity Tests; Streptogramin A; Streptogramin B; Streptogramins | 2006 |
In vitro pharmacokinetic/pharmacodynamic activity of NXL103 versus clindamycin and linezolid against clinical Staphylococcus aureus and Streptococcus pyogenes isolates.
Topics: Acetamides; Anti-Bacterial Agents; Clindamycin; Drug Combinations; Humans; Linezolid; Male; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Oxazolidinones; Staphylococcal Infections; Staphylococcus aureus; Stem Cells; Streptococcal Infections; Streptococcus pyogenes; Streptogramin A; Streptogramin B | 2011 |
Synergy of streptogramin antibiotics occurs independently of their effects on translation.
Topics: Anti-Bacterial Agents; Crystallography, X-Ray; Drug Combinations; Drug Synergism; Enterococcus faecalis; Escherichia coli; Haemophilus influenzae; Microbial Sensitivity Tests; Protein Biosynthesis; Ribosomes; Staphylococcus aureus; Streptococcus pneumoniae; Streptogramin A; Streptogramin B; Streptogramins; Virginiamycin | 2014 |